REGULATORY

• June Approval Likely for Chugai’s NTRK-Gene Targeting Entrectinib, 2nd Tumor-Agnostic Drug
  May 31, 2019

• LDP Junior Politicians Set Up Vaccine Study Group
  May 31, 2019

• “Drugs for Specific Use” Might Include NTD Medicines: MHLW Official
  May 30, 2019

• Chuikyo Subcommittee Agrees on Discussion Timeline, Topics for 2020 Drug Pricing Reform
  May 30, 2019

• MHLW Panel OKs Public Knowledge-Based Applications for Add’l Indication for Rituxan
  May 30, 2019

• Japan Approves Health Coverage for Cancer Gene Panel Tests
  May 30, 2019

• Alnylam’s RNAi Drug Now in Line for Japan Approval in June
  May 29, 2019

• Japan’s 2nd Enbrel Biosimilar, Pfizer’s Herceptin Follow-On Get Listing
  May 28, 2019

• Quizartinib Added to List of MHLW Panel Review on May 30
  May 24, 2019

• LDP’s Life Science Study Group Eyes Enhancement of Databases, AMED Functions
  May 23, 2019

• MHLW Approves Entyvio’s Crohn’s Disease Indication and More
  May 23, 2019

• JPMA Prods Revamp of PMP, Launch Premiums, Comparator Selection Criteria towards 2020 Reform
  May 22, 2019

• Minister Says Kymriah Pricing Appropriate Even with Low Cost Disclosure Ratio
  May 22, 2019

• MHLW Planning to Launch Report System on Inappropriate Detailing Activity as Early as Summer
  May 21, 2019

• Govt, Industry Share Views on Challenges in Data Use, Drug Pricing
  May 21, 2019

• 74 Suspected Violations Found in Sales Reps’ Advertising Activities: MHLW
  May 21, 2019

• Eli Lilly Ordered to Issue Blue Letter on Verzenio
  May 20, 2019

• Kymriah’s Impact on Health Insurance Finances Limited for Now: Health Minister
  May 20, 2019

• LDP Lawmaker Group Discusses Measures for APIs to Ensure Stable Generic Drug Supplies
  May 17, 2019

• Chugai’s Entrectinib Up for Review for NTRK Tumors on May 30; Label Expansions for Lynparza, Cyramza Also on Agenda
  May 17, 2019

ページ

• « 先頭
• ‹ Prev
• …
• 200
• 201
• 202
• 203
• 204
• 205
• 206
• 207
• 208
• …
• Next ›
• 最終 »